Mazor Robotics Ltd., the developer of Renaissance™, an innovative surgical guidance system and its complementary products, announced today that it has received an order for a Renaissance system from Transmedic Pte Ltd., its distribution partner in Southeast Asia. The purchase of the system by Transmedic is another step in Mazors’ footprint expansion and momentum throughout the Asia Pacific region.
This order demonstrates the continued market acceptance of Mazor Robotics’ Renaissance system in the Asia Pacific market with systems already in clinical use in Taiwan, Vietnam and India. Mazor is targeting the Asia Pacific region as a prime market following the U.S. market, and established distribution agreements in China, Japan and Australia.
“Asia Pacific represents a significant growth opportunity for Mazor,” commented Ori Hadomi, Chief Executive Officer. “We are very pleased with our recent success in the Asia Pacific market, both at the clinical utilization level as well as at the expansion of our install base. I believe these developments continue to validate our business and sales model in the international markets, particularly in Asia Pacific.”
Transmedic Pte Ltd. was founded in 1980 and is headquartered in Singapore. Transmedic represents a wide range of medical device manufacturers and its reputation has been built upon its success of collaborating with surgical robotic companies in the Asia Pacific markets.
Mazor Robotics is dedicated to the development and marketing of innovative surgical robots and complementary products that provide a safer surgical environment for patients, surgeons, and operating room staff. Mazor Robotics’ flagship product, Renaissance™, is a state-of-the-art surgical robotic system that enables surgeons to conduct spine surgeries in an accurate and secure manner. Mazor Robotics systems have been successfully used in the placement of over 35,000 implants worldwide. Numerous peer-reviewed publications and presentations at leading scientific conferences have validated the accuracy, usability, and clinical advantages of Mazor Robotics technology. For more information, the content of which is not part of this press release, please visit www.mazorrobotics.com, the content of which does not form a part of this press release.